Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells

Endocrine Research

Volumn 39, Issue 2, 2014, Pages 67-73

  Yin, Shi Nan ^a   Liu, Min ^a   Jing, Dan Qing ^a   Mu, Yi Ming ^a   Lu, Ju Ming ^a   Pan, Chang Yu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Angiotensin receptor blockers; Lipoprotein; Peroxisome proliferator activated receptor; Telmisartan

Indexed keywords

LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INDUCTION; HUMAN; HUMAN CELL; LIPID METABOLISM; LIVER CELL; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CYTOLOGY; DRUG EFFECTS; DYSLIPIDEMIAS; GENE EXPRESSION; GENETICS; HEPG2 CELL LINE; METABOLISM; MYOBLAST;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DYSLIPIDEMIAS; GENE EXPRESSION; HEP G2 CELLS; HUMANS; LIPOPROTEIN LIPASE; MYOBLASTS; PPAR ALPHA; RNA, MESSENGER;

EID: 84898413652     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.3109/07435800.2013.828741     Document Type: Article

References (43)

1. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
2. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
3. Julius S, Kjeldsen SE, Weber M, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
4. Inoue T, Morooka T, Moroe K, et al. Effect of telmisartan on cholesterol levels in patients with hypertension-Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007;39:372-6.
5. Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007;24: 146-53.
6. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27:457-64.
7. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43: 993-1002.
8. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005;54:3442-52.
9. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7.
10. Jing DQ, Yin SN, Mu YM. Angiotensin type II receptor antagonist activates PPARgamma. Chinese J Diabetes 2008;16:375-8.
11. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-97.
12. Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.
13. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11.
14. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70.
15. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98: 2088-93.
16. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsat-urated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997;94:4312-7.
17. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific tran-scriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-48.
18. Kehrer JP, Biswal SS, La E, et al. Inhibition of peroxisome-proliferator- activated receptor (PPAR)a by MK886. Biochem J 2001;356:899-906.
19. Jing DQ, Yin SM, Mu YM. Angiotensin type 1 receptor blockers telmisartan and irbesartan activate PPARa Chinese. J Endocrinol Metabol 2009;25:70-4.
20. Johnson TE, Holloway MK, Vogel R, et al. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. J Steroid Biochem Mol Biol 1997;63:1-8.
21. Nagao Y, French BA, Cai Y, et al. Inhibition of PPAR alpha/RXR alpha-mediated direct hyperplasia pathways during griseofulvin-induced hepatocarcinogenesis. J Cell Biochem 1998;69:189-200.
22. Fan CY, Pan J, Usuda N, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998;273:15639-45.
23. Peters JM, Hennuyer N, Staels B, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997;272:27307-12.
24. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790-3.
25. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 1996;137:354-66.
26. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319-27.
27. Loviscach M, Rehman N, Carter L, et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 2000;43:304-11.
28. Escher P, Braissant O, Basu-Modak S, et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142:4195-202.
29. Clemenz M, Frost N, Schupp M, et al. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008;57: 1405-13.
30. Shimasaki M, Yamashita K, Imanishi RK, et al. Pharmakokinetics of 14C-telmisartan: absorption, distribution and protein binding of 14C-telmisartan after a single oral administration to rats. Xenobio Metab Disp 1999;14:425-31.
31. Entzeroth M, Ebner TJS, Hadamovsky S. Distribution of telmi-sartan in rat liver and binding to cytosol and cytosolic proteins. J Hum Hypertens 1999;13:43 (Abstract).
32. He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension 2010;55:869-79.
33. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005;54:3358-70.
34. Hiuge A, Tenenbaum A, Maeda N, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007;27: 635-41.
35. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-3.
36. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004;114: 1564-76.
37. Toyoda T, Kamei Y, Kato H, et al. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity 2008;16:1199-207.
38. Sugimoto K, Qi NR, Kazdová L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006;47:1003-9.
39. Auwerx J, Leroy P, Schoonjans K. Lipoprotein lipase: recent contributions from molecular biology. Crit Rev Clin Lab Sci 1992; 29:243-68.
40. Hitsumoto T, Takahashi M, Iizuka T, Shirai K. Effect of the angiotensin II receptor antagonist telmisartan on lipoprotein lipase mass in preheparin serum. J Atheroscler Thromb 2008;15:138-45.
41. Lawrence JW, Li Y, Chen S, et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 2001; 276:31521-7.
42. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of per-oxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 2001;276:27950-8.
43. Rakhshandehroo M, Sanderson LM, Matilainen M, et al. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res 2007; 2007:26839-52.